Tuberculous meningitis (TBM) is the most devastating form of tuberculosis (TB) and often causes critical illness with high mortality. A primary management objective is reducing intracranial pressure (ICP), and optimising cerebral perfusion, whilst killing the bacteria and controlling intra-cerebral inflammation. However, the evidence base guiding the care of critically ill patients with TBM is poor and many patients do not have access to neurocritical care units. Invasive ICP monitoring is often unavailable; whilst new non-invasive monitoring techniques show promise, further evidence for their use is required. Optimal management of neurological complications, and of hyponatraemia, which frequently accompanies TBM, is not known. The best supportive care remains uncertain. Recent advances in the field of TBM predominantly focus upon diagnosis, inflammatory processes and anti-TB chemotherapy. Clinical trials are required to provide robust evidence guiding the most effective supportive, therapeutic and neurosurgical interventions in TBM, with proven benefits for morbidity and mortality.